Human VEGFR2/KDR DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human VEGFR2/KDR DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: KDR

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGFR2/KDR DuoSet ELISA, 15 Plate

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Publications for VEGFR2/KDR/Flk-1 (DY357)(8)

Publications using DY357

• FDD Nunes, LP Ferezin, SC Pereira, FV Figaro-Dru, LC Pinheiro, IC Menezes, CVW Baes, FB Coeli-Lacc, JE Tanus-Sant, MF Juruena, R Lacchini The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression Pharmaceutics, 2022-12-09;14(12):. 2022-12-09 [PMID: 36559251] (Human)
• I Wada, S Nakao, M Yamaguchi, Y Kaizu, M Arima, S Sawa, KH Sonoda Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1+ Macrophage Infiltration Investigative Ophthalmology & Visual Science, 2021-10-04;62(13):17. 2021-10-04 [PMID: 34673901] (Human)
• K Shuto, M Mori, C Kosugi, K Narushima, S Nakabayash, T Fujisiro, A Sato, K Hayano, H Shimizu, K Koda Hepatic blood flow by perfusion computed tomography as an imaging biomarker for patients with gastric cancer Oncol Lett, 2019-01-25;17(3):3267-3276. 2019-01-25 [PMID: 30867759] (Human)
• Kumar N, Moideen K, Sivakumar S, Menon P, Viswanathan V, Kornfeld H, Babu S Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2016-10-04;74(1):10-21. 2016-10-04 [PMID: 27717783] (Human)
• Kumar N, Banurekha V, Nair D, Babu S Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE, 2016-01-04;11(1):e0146318. 2016-01-04 [PMID: 26727122] (Human)
• Conroy A, Gelvez M, Hawkes M, Rajwans N, Liles W, Villar-Centeno L, Kain K Host biomarkers distinguish dengue from leptospirosis in Colombia: a case-control study. BMC Infect Dis, 2014-01-20;14(0):35. 2014-01-20 [PMID: 24444080] (Human)
• Munaut C, Lorquet S, Pequeux C, Coulon C, Le Goarant J, Chantraine F, Noel A, Goffin F, Tsatsaris V, Subtil D, Foidart JM Differential expression of Vegfr-2 and its soluble form in preeclampsia. PLoS ONE, 2012-03-12;7(3):e33475. 2012-03-12 [PMID: 22428059] (Human)
• Kishuku M, Nishioka Y, Abe S, Kishi J, Ogino H, Aono Y, Azuma M, Kinoshita K, Batmunkh R, Rentsenhand B, Makino H, Ranjan P, Minakuchi K, Sone S Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J. Immunol., 2009-12-15;183(12):8176-85. 2009-12-15 [PMID: 20007583] (Human)

FAQs for VEGFR2/KDR/Flk-1 (DY357). (Showing 1 - 1 of 1 FAQs).

1. What is the difference between the Quantikine and Duoset ELISA kits?
   • Our Quantikine kits are fully optimized and validated for the sample types listed on the product specific webpage and datasheet, as this can vary between kits. Each kit is supplied ready to use with one pre-coated 96-well plate, a detection antibody directly conjugated to HRP, and all other necessary reagents. These kits are ideal for researchers who want the convenience of a ready to use and optimized ELISA product. Some of these kits are also available prepackaged in larger 6 and 50 plate sizes.Our DuoSet Kits, in contrast, are ELISA development kits containing the capture and detection antibody, the mass-value calibrated standard, and streptavidin-HRP to prepare approximately 5 or 15 plates. Ancillary reagents will need to be used/purchased, and for most kits, we will recommend one of our Ancillary Reagent Kits, which contain the reagents we use ourselves in-house. DuoSet kits are validated only for cell culture supernatant samples and therefore require further development and validation for accurate measurement in more complex samples such as serum and plasma. Our DuoSet Kits offer an economical, flexible alternative for the experienced ELISA user.

Bioinformatics

• Gene Symbol: KDR